Research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy in non-small cell lung cancer
10.3760/cma.j.issn.1004-4221.2017.10.024
- VernacularTitle:miRNAs与非小细胞肺癌EGFR突变及放疗相关性研究进展
- Author:
Qizhen XU
1
;
Daxin ZHANG
Author Information
1. 福建医科大学附属协和医院放疗科
- Keywords:
Carcinoma;
non-small cell lung/radiotherapy;
Epidermal growth factor receptor;
Tyrosine kinase inhibitor
- From:
Chinese Journal of Radiation Oncology
2017;26(10):1222-1226
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor ( EGFR) is most popular in targeted therapy for non-small cell lung cancer ( NSCLC ) . In recent years, there have been a great number of molecular biology studies of EGFR. Radiotherapy is well-known as a traditional and important treatment for NSCLC, and the treatment outcome is associated with EGFR mutation and overexpression. Phase Ⅲ trials are needed to evaluate the effect of a combination of radiotherapy and EGFR-tyrosine kinase inhibitor ( EGFR-TKI) in the treatment of NSCLC. MicroRNAs ( miRNAs) can modulate tumor-associated gene expression and influence the biological process of tumor. Recent studies have demonstrated that miRNAs play a positive or negative role in EGFR mutation, EGFR-TKI treatment, and radiotherapy, which mechanism has been partially clarified. In this article, we review the research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy, so as to provide the latest evidence for the application of miRNAs in the combination of radiotherapy and EGFR-TKI for the treatment of NSCLC.
